47 results about "Malignant pleural effusion" patented technology

A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject. This method has advantages to present diagnostic procedures for identifying malignant pleural effusions. The tumor cells present in pleural fluid can be characterized with cellular and molecular markers to determine prognostic and predictive factors.

The invention discloses a traditional Chinese medicine composition for treating the malignant pleural effusion. The malignant pleural effusion belongs to the scope of pleural effusions in fluid-retention syndromes in the traditional Chinese medicine. The pathogenesis mainly comprises asthenia in origin, asthenia in superficiality and intermingled deficiency and excess, wherein the asthenia in origin refers to lung, spleen and kidney qi deficiency, and the asthenia in superficiality refers to turbid phlegm, retained fluid, blood stasis and stagnation of the circulation of vital energy. Traditional Chinese medicines including jacobinia suberecta, veronicastrum herbs, potentilla parvifolia fisch, fringed iris herbs, wusuli dragonflyorchis rhizome, phaenosperma globosa, chorion ovi, field sowthistle herb, polygonatum verticillatum, paris polyphylla, solanum lyratum and Indian strawberry which have the effects of invigorating the spleen for eliminating dampness, purging the lung of pathogenic fire to facilitate water retention and relieving internal heat or fever to resist cancers are selected for preparing the traditional Chinese medicine composition, and the traditional Chinese medicine is decocted with water to form decoctions. Clinical tests in the hospital show that the total effective rate is 94.1%, and the treatment effect is remarkable.

The invention provides a drug for treating malignant pleural effusion with Qi and Yin deficiency, comprising materials: Radix Codonopsis, Radix Acanthopanacis Semticosi, Radix Scrophulariae, Semen Plantaginis, Semen Lepidii, Herba Ephedrae, Ramulus Cinnamomi, Radix et Rhizoma Rhei, Cortex Mori, Rhizoma Dioscoreae, Herba Orchidis Latifoliae, Radix Morinaceae, Radix Araliae, Radix Asparagi, Flos lonicerae, Herba Cymbopogonis, Herba seu Radix Asteris Ageratozdis, and pollen typhae. An effective means to treat malignant pleural effusion is given using the drug with chemotherapy through pleural perfusions, thus recurrence rate of pleural effusion of lung cancer is decreased and curative effect is improved, toxic and side effects of chemotherapy can also be relieved and the curative effect can also be enhanced, by using traditional Chinese medicine, and meanwhile, life quality of a patient is improved and clinical symptoms are relieved, both the entirety and locality of the patient are cared and the purpose of strengthening body resistance and eliminating evil is achieved.

The invention relates to an inoculation liquid composition and a method for building a malignant pleural effusion sourced xenotransplantation tumor animal model by using the inoculation liquid composition. The inoculation liquid provided by the invention contains the following ingredients including Hank' blanace salt buffer solution, fetal calf serum, basement membrane substrate glue and ROCK protein inhibitor. The method for building the malignant pleural effusion sourced xenotransplantation tumor animal model provided by the invention comprises the steps of collecting a clinic malignant pleural effusion sample, enriching tumor cells, using inoculation liquid suspension cells provided by the invention, and inoculating the cells into an animal so as to form xenotransplantation tumor. The model building method provided by the invention has the advantages that simplicity is easy; the implementation is easy; the tumor forming rate is high, so that the method can be used for medicine screening and mechanism study of various kinds of cancer with malignant pleural effusion.

The invention discloses lentinan nano-selenium, a preparation method and application of the lentinan nano-selenium in treatment of malignant pleural effusion. The preparation method comprises the following steps: (1) respectively dissolving lentinan, sodium selenite and ascorbic acid in water to obtain corresponding solutions; (2) uniformly mixing the lentinan solution with a sodium selenite solution and an ascorbic acid solution respectively to obtain a lentinan/sodium selenite mixed solution and a lentinan/ascorbic acid mixed solution; and (3) dropwise adding the lentinan/sodium selenite mixed solution into the lentinan/ascorbic acid mixed solution, and conducting stirring for reaction to obtain the lentinan nano-selenium. Through comparison, it is found that the lentinan nano-selenium prepared through the method can be taken by immune cells in malignant pleural effusion (MPE), MPE in a cold state is converted into functional hot state, the immune function of a patient is improved, and therefore the lentinan nano-selenium can be used for treating tumors and malignant pleural effusion.

The invention relates to an isolated culture method of malignant pleural effusion-sourced TIL cells. The isolated culture method comprises the following steps: using at least one of PD-1, LAG-3 and TIM-3 as a marker for isolating tumor-specific T lymphocytes from TIL cells, isolating the tumor-specific T lymphocytes from a TIL cell population in combination with an immunomagnetic bead technology, and performing in-vitro efficient amplification to obtain tumor-specific TIL cells with high tumor-killing activities. By the isolated culture method, the isolated culture of the tumor-specific TIL cells is simpler in operational process and the isolated culture time is significantly shortened; the isolated culture method is low in cost and convenient to popularize and apply; in addition, the tumor-killing activities of the isolated tumor-specific TIL cells are stronger.

The invention belongs to the technical field of malignant pleural effusion detection methods, and specifically relates to a method for identifying the malignant pleural effusion by using CD14+CD163+cells. The method comprises the following steps of extracting mononuclear cells, labeling antibodies, and performing immunophenotyping analysis by using a flow cytometry. Compared with the prior art, the method provided by the invention has the advantages that the method is simple and convenient and rapid, the sensitivity is high, the specificity is high, meanwhile, the interference of man-made subjective factors is reduced by using the method, the method is objective, judgment and identification can be made for the potential malignant pleural effusion patient as soon as possible, and convenience is provided for the subsequent in-time intervention treatment.

The invention belongs to the field of biological sample detection and discloses an application of a non-small cell lung cancer pleural effusion tumor marker. SP70 is used as the non-small cell lung cancer pleural effusion tumor marker to be applied to preparation of non-small cell lung cancer pleural effusion and/or pleural effusion cast-off cell diagnostic reagents. A monoclonal antibody of the SP70 is applied to preparation of the non-small cell lung cancer pleural effusion and/or pleural effusion cast-off cell diagnostic reagents. A direct immunofluorescence detection kit of non-small cell lung cancer pleural effusion cast-off cells contains the fluorescently-labeled monoclonal antibody of the SP70, 5% of bovine serum albumin (BSA) and 1% of a phosphate buffer solution (PBS). According to a great quantity of experimental researches, SP70 antigens can serve as a sensitive and specific detection index of malignancy pleural effusion caused by non-small cell lung cancers, simultaneously, the SP70 antigens in the pleural effusion and the pleural effusion cast-off cells can be detected, and sensitivity and specificity of carcinogenic pleural effusion diagnosis can be greatly improved.

The present disclosure provides a novel pharmaceutical composition for treating a malignant pleural effusion (MPE), including a benzenesulfonamide derivative and a pharmaceutically acceptable excipient. The present disclosure further provides a method for treating MPE by using the pharmaceutical composition.

The invention discloses a micromolecular marker for the diagnosis of malignant pleural effusion and an application thereof, wherein the micromolecular marker comprises the following 11 compounds of: valine, lactate, alanine salt, acetacetate, creatinine, trimethyl-amine oxide, betaine, alpha- and beta-glucose, leucine and isoleucine. In allusion to the components of pleural effusion of cancer patients and the content variation of the components, the micromolecular marker, which has strong specificity, high sensitivity and high appraisal result accuracy and is used for the diagnosis of malignant pleural effusion, is selected by the combination of the nuclear magnetic resonance technology and the stepwise discriminant function analysis method; in particular, lactate, acetacetate, trimethyl-amine oxide, betaine and alpha-glucose can sensitively, accurately and efficiently identify benign and malignant pleural effusion, which is of great significance for accurately diagnosing malignant pleural effusion such as lung cancer at an early stage, striving for much more treatment time for patients and raising the clinic treatment effect.

The invention provides an analysis method for a volatile organic compound in pleural effusion. The method comprises the steps of headspace solid phase microextraction, cold trap focusing and gas chromatographic and mass spectrometry combination. The method with the combination of the cold trap focusing and gas chromatographic and mass spectrometry combination on the basis of the headspace solid phase microextraction technology can rapidly and accurately analyze the volatile organic compound in the pleural effusion. According to the analysis method, extraction, enrichment and sample introduction are integrated into headspace solid phase microextraction, operation is easy and convenient, no complex pretreatment process is needed, complex matrix interference of biological samples is eliminated, and component information distortion in samples is not caused; due to the cold trap focusing technology, the high-volatility organic compound in the pleural effusion is condensed and secondarily analyzed at low temperature and effectively separated on the proper chromatographic condition. According to the analysis method, the volatile organic compound in the pleural effusion can be rapidly detected, quanlitative and semi-quantitative analysis is performed, and the analysis method is of great importance in distinguishing benign and malignant pleural effusion and even screening lung cancer markers by applying difference analysis.

The invention relates to a tumor treatment method for patients with terminal malignant tumor lung metastasis with malignant pleural effusion. The method includes the steps: draining and collecting pleural effusion from cancerous hydrothorax appearing in a patient with lung metastasis, centrifuging and enriching, then separating out metastatic pleural effusion mononuclear cells (PEMC), adjusting the concentration of 5*10<5>/ml in pores of a 24-pore plate, placing in an incubator, amplifying the PEMC with combined application of peripheral blood mononuclear cells (PBMC) in healthy adults after irradiation with IL-2, and taking the PBMC after irradiation as trophocytes to stimulate the amplification and cytotoxicity tests of the PEMC. The invention also provides a use of the PEMC prepared bythe method in preparation of drugs for treating terminal malignant tumor lung metastasis with malignant pleural effusion. The advantages show that provided is a PEMC amplification method with higher efficiency and relatively convenient technology, the amplification efficiency reaches 1000 times, and high cytotoxicity killing effect is achieved.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine dressing for treating malignant pleural effusion. After the malignant pleural effusion is treated by conventional methods such as systemic chemotherapy, local treatment in the thoracic cavity, thermal therapy and surgical treatment, the recurrence rate in a short period is relatively high. In order to solve the problems, the traditional Chinese medicine dressing for treating malignant pleural effusion, provided by the invention, is prepared from astragalus membranaceus, semen pharbitidis, polyporus umbellatus, semen coicis, radix stephaniae tetrandrae, rhizoma alismatis, herba lycopi, zanthoxylum bungeanum maxim, borneol, garden balsam stem, poria cocos, cassia twig, ground beetle, areca-nut, nightshade, pericarpium arecae, euphorbia kansui and leech. The traditional Chinese medicine dressing is obtained through optimization based on an existing prescription, and has an outstanding treatment effect on malignant pleural effusion and can effectively control the increase of pleural effusion.

The invention provides a traditional Chinese medicine for treating lung cancer patients with malignant pleural effusion in combination with ultrasonic intervention and a preparation method. The traditional Chinese medicine comprises the following raw medicine materials: Chinese violet, przewalsk rhododendron flower, lupulus, scandent hedyotis herb, duhat fruit, aster auriculatus, negundo chastetree leaf, physalis angulata, oxystelma esculentum, unarmed glorybower root, guava leaf, lantern plant calyx, adiantum capillus veneris, cavalerie clearweed herb, wild alfalfa, largeserrate angelica root and willowleaf spiraea herb and root. The traditional Chinese medicine provided by the invention has the beneficial effects of being capable of treating lung cancer patients with malignant pleural effusion in combination with ultrasonic intervention and pleural chemotherapy, convenient to use, capable of obviously improving the curative effect on malignant pleural effusion, free of toxic or side effect, less in adverse reaction and simple in preparation process.